<DOC>
	<DOCNO>NCT00291928</DOCNO>
	<brief_summary>The purpose trial primarily investigate safety profile HuMax-CD20 patient active RA . Furthermore , trial design identify dose level use future trial ( base evaluation safety , pharmacokinetics ACR DAS response ) .</brief_summary>
	<brief_title>HuMax-CD20 Active Rheumatoid Arthritis , Phase I/II</brief_title>
	<detailed_description>This trial consist double-blind , placebo control , dose escalation part randomization trial treatment within three sequential cohort ( Part A ) , parallel group part randomization one four treatment arm ( Part B ) . Patients Parts A B receive two infusion either HuMax-CD20 ( 300 mg , 700 mg , 1000 mg ) placebo follow safety , efficacy , pharmacokinetic measurement 24 week . Hereafter patient follow every 12 week B-cells ( CD19+ cell ) return baseline level . For patient Part B , follow-up visit 36 48 week initial trial treatment ( Follow-up Visits 1 2 ) include additional measurement safety efficacy .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Age ≥ 18 year Active rheumatoid arthritis accord American College Rheumatology least six month duration six swollen six tender joint ( 28 joint ) Erythrocyte Sedimentation Rate ( ESR ) ≥ 22 mm/h and/or CReactive Protein ( CRP ) ≥ 10 mg/L ( 1 mg/dL ) . Treatment failure one DMARDs . Treatment methotrexate ( 7.525 mg/wk ) least 12 week stable dose least 4 week prior plan start trial treatment . Use DMARDs methotrexate . Current previous ( within four week screen ) participation clinical trial . Previous exposure biological product within 4 week prior plan start trial treatment , and/or exposure antiCD20 antibody within two year screen trial . Any use cyclophosphamide , nitrogen mustard , chlorambucil alkylating agent within five year screen trial . Active autoimmune disease ( RA RAassociated secondary disease ) require immunosuppressive therapy . Past current malignancy , except resect cervical carcinoma Stage 1B less , noninvasive basal cell squamous cell skin carcinoma , malignant melanoma complete response duration &gt; 10 year , cancer diagnosis complete response duration &gt; 5 year . Chronic current infectious disease include know suspected positive serology HIV , hepatitis B , hepatitis C. Clinically significant cardiac disease , history significant cerebrovascular disease . Significant concurrent , uncontrolled medical condition include , limited : renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , neurological , cerebral , psychiatric disease . Breast feeding woman , woman positive pregnancy test screening , woman childbearing potential willing use adequate contraception trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>